作者感谢西班牙国家科学与创新部长 (MICINN)(授权号 CTQ2007-65218)、Consolider Ingenio(授权号 2010-CSD-2007-00006 和 CTQ2011-24165)、Generalitat Valenciana(授权号为039)、Fondos Europeos para el Desarrollo Regional (FEDER) 和阿利坎特大学的财政支持。
[EN] COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE TRK
申请人:IRM LLC
公开号:WO2012034095A1
公开(公告)日:2012-03-15
The invention provides compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. wherein: and the rest of the variables are as specified in the claims.
[EN] COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE TRK
申请人:IRM LLC
公开号:WO2012116217A1
公开(公告)日:2012-08-30
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
wherein:
A is
X1 is CH or N;
Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.